Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato A C, Bartsch G, Klocker H
Department of Urology, University of Innsbruck, Austria.
Prostate. 1998 Apr 1;35(1):63-70. doi: 10.1002/(sici)1097-0045(19980401)35:1<63::aid-pros9>3.0.co;2-i.
Endocrine therapy for prostate cancer aims to reduce the levels of circulating androgen or to inhibit androgen action by blocking the androgen receptor in the prostate, or both. Studies in various animal and human prostate cancer models suggested that there may be a downregulation of androgen receptor during prostate cancer progression. Recent work, however, showed androgen receptor expression in all stages of prostate cancer. The presence of mutant androgen receptors in a portion of prostate cancers and receptor activation in the absence of androgen or in the presence of low androgen concentrations is discussed within this context.
This review attempts to summarize the literature on androgen receptor expression in vitro and in vivo, as well as structural and functional alterations and communication between androgen signal transduction cascade and other signaling pathways.
Prostate tumors adapt to an environment with low androgen supply by using a hyperactive androgen receptor. The mechanisms involved are mutations of the androgen receptor generating receptors with broadened activation spectrum, increased receptor expression, and activation by interaction with other signaling pathways.
前列腺癌的内分泌治疗旨在降低循环雄激素水平,或通过阻断前列腺中的雄激素受体来抑制雄激素作用,或两者兼而有之。在各种动物和人类前列腺癌模型中的研究表明,在前列腺癌进展过程中雄激素受体可能会下调。然而,最近的研究显示雄激素受体在前列腺癌的各个阶段均有表达。在此背景下,讨论了一部分前列腺癌中突变雄激素受体的存在以及在无雄激素或低雄激素浓度情况下的受体激活。
本综述试图总结关于雄激素受体在体外和体内表达的文献,以及雄激素信号转导级联与其他信号通路之间的结构和功能改变及相互作用。
前列腺肿瘤通过使用高活性雄激素受体来适应低雄激素供应的环境。涉及的机制包括雄激素受体突变产生具有更广泛激活谱的受体、受体表达增加以及通过与其他信号通路相互作用而激活。